Aerts HJ, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
Afshar-Oromieh A, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.
Agasti SS, Rana S, Park MH, Kim CK, You CC, Rotello VM. Nanoparticles for detection and diagnosis. Adv Drug Deliv Rev. 2010;62:316–28.
Alaei P, Spezi E. Imaging dose from cone beam computed tomography in radiation therapy. Physica Med. 2015;31:647–58.
Alric C, et al. Gadolinium chelate coated gold nanoparticles as contrast agents for both x-ray computed tomography and magnetic resonance imaging. J Am Chem Soc. 2008;130:5908–15.
Barreto JA, O’Malley W, Kubeil M, Graham B, Stephan H, Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater. 2011;23:H18–40.
Brahme A. Individualizing cancer treatment: biological optimization models in treatment planning and delivery. Int J Radiat Oncol Biol Phys. 2001;49:327–37.
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631–51.
Butterworth KT, McMahon SJ, Currell FJ, Prise KM. Physical basis and biological mechanisms of gold nanoparticle radiosensitization. Nanoscale. 2012;4:4830–8.
Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007;30:637–44.
Cole LE, Ross RD, Tilley JMR, Vargo-Gogola T, Roeder RK. Gold nanoparticles as contrast agents in x-ray imaging and computed tomography. Nanomedicine. 2015;10:321–41.
Cormode DP, et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology. 2010;256:774–82.
Coulter JA, Hyland WB, Nicol J, Currell FJ. Radiosensitising nanoparticles as novel cancer therapeutics - pipe dream or realistic prospect? Clin Oncol. 2013;25:593–603.
Coulter JA, Butterworth KT, Jain S. Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy. Br J Radiol. 2015;88:20150256.
Detappe A, Kunjachan S, Drané P, Kotb S, Myronakis M, Biancur DE, Ireland T, Wagar M, Lux F, Tillement O, Berbeco R. Key clinical beam parameters for nanoparticle-mediated radiation dose amplification. Sci Rep. 2016;6:34040.
Fan Q, Nanduri A, Mazin S, Zhu L. Emission guided radiation therapy for lung and prostate cancers: a feasibility study on a digital patient. Med Phys. 2012;39:7140–52.
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563–77.
Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM. Nanoparticles as contrast agents for in vivo bioimaging: current status and future perspectives. Anal Bioanal Chem. 2011;399:3–27.
Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49:N309–15.
Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006;79:248–53.
Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. J Pharm Pharmacol. 2008;60:977–85.
Han T, Mikell JK, Salehpour M, Mourtada F. Dosimetric comparison of Acuros XB deterministic radiation transport method with Monte Carlo and model-based convolution methods in heterogeneous media. Med Phys. 2011;38:2651–64.
Harrington KJ, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011;105:628–39.
Hatton JA, et al. Does the planning dose-volume histogram represent treatment doses in image-guided prostate radiation therapy? assessment with cone-beam computerised tomography scans. Radiother Oncol. 2011;98:162–816.
Hoskin P, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397–406.
Hoyer M, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–30.
Hyland WB, McMahon SJ, Butterworth KT, Cole AJ, King RB, Redmond KM, Prise KM, Hounsell AR, McGarry CK. Investigation into the radiobiological consequences of pre-treatment verification imaging with megavoltage X-rays in radiotherapy. Br J Radiol. 2014;87:20130781.
Jain S, et al. Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys. 2011;79:531–9.
Johnson TRC, et al. Material differentiation by dual energy CT: initial experience. Eur Radiol. 2007;17:1510–7.
Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363:2434–43.
King RB, et al. An in vitro study of the radiobiological effects of flattening filter free radiotherapy treatments. Phys Med Biol. 2013;58:N83–94.
Krämer M, Scholz M. Treatment planning for heavy-ion radiotherapy: calculation and optimization of biologically effective dose. Phys Med Biol. 2000;45:3319–30.
Lambin P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.
Lee N, Choi SH, Hyeon T. Nano-sized CT contrast agents. Adv Mater. 2013;25:2641–60.
Lin G, Zhang H, Huang L. Smart polymeric nanoparticles for cancer gene delivery. Mol Pharm. 2015;12:314–21.
Lin Y, McMahon SJ, Scarpelli M, Paganetti H, Schuemann J. Comparing gold nano-particle enhanced radiotherapy with protons, megavoltage photons and kilovoltage photons: a Monte Carlo simulation. Phys Med Biol. 2014;59:7675–89.
Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–60.
Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine. 2008;3:703–17.
Lütje S, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5:1388–401.
Marks LB, et al. Enhancing the role of case-oriented peer review to improve quality and safety in radiation oncology: executive summary. Pract Radiat Oncol. 2013;3:149–56.
McMahon SJ, et al. Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy. Radiother Oncol. 2011;100:412–6.
McMahon SJ, et al. Cellular signalling effects in high precision radiotherapy. Phys Med Biol. 2015;60:4551–64.
Moffat BA, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA. 2005;102:5524–9.
Nam J, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science. 2003;301:1884–6.
Oelfke U. Magnetic resonance imaging-guided radiation therapy: technological innovation provides a new vision of radiation oncology practice. Clin Oncol. 2015;27:495–7.
Panyama J, Labhasetwara V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55:329–47.
Particle Therapy Co-Operative Group (PTCOG). Facilities in Operation. 2016a. http://www.ptcog.ch/index.php/facilities-in-operation. Accessed 22 June 2016.
Particle Therapy Co-Operative Group (PTCOG). Facilities under Construction. 2016b. http://www.ptcog.ch/index.php/facilities-under-construction. Accessed 22 June 2016.
Perini R, Choe R, Yodh AG, Sehgal C, Divgi CR, Rosen MA. Non-invasive assessment of tumor neovasculature: techniques and clinical applications. Cancer Metastasis Rev. 2008;27:615–30.
Porcel E, et al. Gadolinium-based nanoparticles to improve the hadrontherapy performances. Nanomedicine. 2014;10:1601–8.
Ramm U, Damrau M, Mose S, Manegold KH, Rahl CG, Böttcher HD. Influence of CT contrast agents on dose calculations in a 3D treatment planning system. Phys Med Biol. 2001;46:2631–5.
Reischauer C, et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology. 2010;257:523–31.
Sancey L, et al. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Br J Radiol. 2014;87:20140134.
Schlomka JP, et al. Experimental feasibility of multi-energy photon-counting K-edge imaging in pre-clinical computed tomography. Phys Med Biol. 2008;53:4031–47.
Schuemann J, et al. Roadmap to clinical use of gold nanoparticles for radiation sensitization. Int J Radiat Oncol Biol Phys. 2016;94:189–205.
Schweitzer AD, et al. Melanin-covered nanoparticles for protection of bone marrow during radiation therapy of cancer. Int J Radiat Oncol Biol Phys. 2010;78:1494–502.
Shilo M, Reuveni T, Motiei M, Popovtzer R. Nanoparticles as computed tomography contrast agents: current status and future perspectives. Nanomedicine. 2012;7:257–69.
Srinivasan K, Mohammadi M, Shepherd J. Applications of linac-mounted kilovoltage cone-beam computed tomography in modern radiation therapy: a review. Pol J Radiol. 2014;79:181–93.
Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60:1252–65.
Thorsten RCJ, et al. Material differentiation by dual energy CT: initial experience. Eur Radiol. 2007;17:1510–7.
Tse BW, et al. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine. 2015;10:375–86.
van Dijk LV et al (2016) CT image biomarkers to improve patient-specific prediction of radiation induced xerostomia and sticky saliva. Radiother Oncol (In Press).
van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004;14:52–64.
Walmsley GG, et al. Nanotechnology in bone tissue engineering. Nanomedicine. 2015;11:1253–63.
Wang AZ, Langer R, Farokhzad OC. Nanoparticle Delivery of Cancer Drugs. Annu Rev of Med. 2012;63:185–98.
Wang AZ, Tepper JE. Nanotechnology in radiation oncology. J Clin Oncol. 2014;32:2879–85.
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82.
Wilkins A, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2015;16:1605–16.
Yamada S, et al. Radiotherapy treatment planning with contrast-enhanced computed tomography: feasibility of dual-energy virtual unenhanced imaging for improved dose calculations. Radiat Oncol. 2014;9:168.
Yang J, Yamamoto T, Mazin SR, Graves EE, Keall PJ. The potential of positron emission tomography for intratreatment dynamic lung tumor tracking: a phantom study. Med Phys. 2014;41:021718.
Yue J, et al. Lipiodol: a potential direct surrogate for cone-beam computed tomography image guidance in radiotherapy of liver tumor. Int J Radiat Oncol Biol Phys. 2012;82:834–41.